BEIJING: A strategic cooperation agreement was signed last week in Beijing between Beijing Yuanxin Huibao Technology Co., Ltd., the Pakistan China Business Association, and Nanjing IASO Biotechnology Co., Ltd. The agreement aims to enhance access to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for adult patients with multiple myeloma in Pakistan.
During the signing ceremony, Tahir Farooq, President of the Pakistan China Business Association, emphasized that this partnership will not only bring advanced CAR-T Therapy to Pakistani patients but also introduce innovative payment models to ease financial burdens and improve drug accessibility, as reported by China Economic Net (CEN) on Tuesday.
Eric Tian, head of overseas operations at IASO Biotechnology, highlighted how this strategic alliance will capitalize on each partner’s strengths to develop innovative treatment solutions, ultimately providing more efficient CAR-T services to patients in Pakistan.
CAR-T Therapy is recognized as a groundbreaking advancement in cell therapy, especially for treating hematological malignancies. According to Peng Xuan, CEO of Yuanxin Huibao, this collaboration will significantly enhance access to CAR-T treatments, allowing more Pakistani patients to benefit from this state-of-the-art therapy.
